<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_ceramides" title="Evaluation of the Filming and Protective Properties of a New Trehalose and Ceramides Based Ingredient" shortTitle="ceramides" author="Letteria Greco, Salviana Ullo, Luigi Rigano, Marco Fontana, Enzo Berardesca, Norma Cameli" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2079-9284/6/4/62/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
3.	LS	3.
</s>
<s type="frag">
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
The	DT	the
statistical	JJ	statistical
analysis	NN	analysis
of	IN	of
the	DT	the
collected	VBN	collect
data	NNS	datum
at	IN	at
each	DT	each
visit	NN	visit
shows	VBZ	show
a	DT	a
very	RB	very
good	JJ	good
trend	NN	trend
for	IN	for
hydrogel	NN	hydrogel
containing	VBG	contain
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
based	VBN	base
ingredient	NN	ingredient
</s>
<s type="frag">
at	IN	at
each	DT	each
visit	NN	visit
:	:	:
</s>
</p>
<p>
<s type="frag">
<b>
Evaporimetry	NNP	Evaporimetry
(	-LRB-	(
Transepidermal	NNP	Transepidermal
Water	NNP	Water
Loss	NNP	Loss
(	-LRB-	(
TEWL	NNP	TEWL
)	-RRB-	)
)	-RRB-	)
</b>
</s>
</p>
<p>
<s type="decl">
Evaporimetry	NN	evaporimetry
was	VBD	be
used	VBN	use
to	TO	to
detect	VB	detect
any	DT	any
influence	NN	influence
on	IN	on
the	DT	the
water	NN	water
barrier	NN	barrier
function	NN	function
of	IN	of
the	DT	the
skin	NN	skin
following	VBG	follow
application	NN	application
of	IN	of
ceramides	NNS	ceramide
and	CC	and
trehalose	NN	trehalose
based	VBN	base
ingredient	NN	ingredient
hydrogel	NN	hydrogel
and	CC	and
placebo	NN	placebo
hydrogel	NN	hydrogel
.	.	.
</s>
</p>
<p>
<s type="frag">
<b>
Corneometry	NNP	Corneometry
(	-LRB-	(
Hydration	NNP	Hydration
)	-RRB-	)
</b>
</s>
</p>
<p>
<s type="decl">
In	IN	in
order	NN	order
to	TO	to
measure	VB	measure
the	DT	the
amount	NN	amount
of	IN	of
water	NN	water
present	JJ	present
in	IN	in
the	DT	the
stratum	NN	stratum
corneum	NN	corneum
and	CC	and
the	DT	the
skin	NN	skin
barrier	NN	barrier
condition	NN	condition
,	,	,
hydration	NN	hydration
has	VBZ	have
been	VBN	be
evaluated	VBN	evaluate
through	IN	through
Corneometry	NNP	Corneometry
.	.	.
</s>
</p>
<p>
<s type="decl">
Moreover	RB	moreover
,	,	,
the	DT	the
T-test	NNP	T-test
applied	VBN	apply
to	IN	to
hydrogel	NN	hydrogel
containing	VBG	contain
ceramides	NNS	ceramide
and	CC	and
trehalose	NN	trehalose
based	VBN	base
ingredient	NN	ingredient
and	CC	and
placebo	NN	placebo
formula	NN	formula
gave	VBD	give
a	DT	a
statistically	RB	statistically
significant	JJ	significant
difference	NN	difference
between	IN	between
them	PRP	they
at	IN	at
each	DT	each
visit	NN	visit
,	,	,
always	RB	always
showing	VBG	show
better	JJR	good
results	NNS	result
for	IN	for
the	DT	the
hydrogel	NN	hydrogel
containing	VBG	contain
ceramides	NNS	ceramide
and	CC	and
trehalose	NN	trehalose
based	VBN	base
ingredient	NN	ingredient
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
double-blind	JJ	double-blind
,	,	,
placebo-controlled	JJ	placebo-controlled
study	NN	study
was	VBD	be
performed	VBN	perform
to	TO	to
assess	VB	assess
,	,	,
by	IN	by
corneometry	NN	corneometry
and	CC	and
evaporimetry	NN	evaporimetry
,	,	,
the	DT	the
barrier	NN	barrier
normalizing	VBG	normalize
efficacy	NN	efficacy
of	IN	of
a	DT	a
topical	JJ	topical
product	NN	product
containing	VBG	contain
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
to	TO	to
alleviate	VB	alleviate
skin	NN	skin
dryness	NN	dryness
on	IN	on
limbs	NNS	limb
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
study	NN	study
results	NNS	result
show	VBP	show
a	DT	a
significant	JJ	significant
moisturizing	JJ	moisturizing
effect	NN	effect
of	IN	of
the	DT	the
ingredient	NN	ingredient
at	IN	at
each	DT	each
visit	NN	visit
,	,	,
both	CC	both
versus	IN	versus
baseline	NN	baseline
and	CC	and
versus	IN	versus
the	DT	the
placebo	NN	placebo
control	NN	control
(	-LRB-	(
<hi rend="italic">
p	NN	p
</hi>
&lt;	SYM	&lt;
0.01	CD	0.01
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="frag">
For	IN	for
the	DT	the
application	NN	application
site	NN	site
of	IN	of
topical	JJ	topical
cosmetic	JJ	cosmetic
formula	NN	formula
containing	VBG	contain
a	DT	a
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
based	VBN	base
ingredient	NN	ingredient
:	:	:
</s>
</p>
<p>
<s type="decl">
(	:	(
1	CD	1
)	-RRB-	)
Transepidermal	NNP	Transepidermal
water	NN	water
loss	NN	loss
(	-LRB-	(
TEWL	NNP	TEWL
)	-RRB-	)
value	NN	value
shows	VBZ	show
a	DT	a
reduction	NN	reduction
of	IN	of
−54	CD	−54
%	NN	%
after	IN	after
4	CD	4
weeks	NNS	week
(	-LRB-	(
</s>
<figure>
<s type="frag">
Figure	NNP	Figure
2	CD	2
</s>
</figure>
<s type="frag">
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="frag">
(	-LRB-	(
2	CD	2
)	-RRB-	)
</s>
<s type="decl">
Hydration	NN	hydration
shows	VBZ	show
an	DT	a
increase	NN	increase
of	IN	of
102	CD	102
%	NN	%
after	IN	after
4	CD	4
weeks	NNS	week
(	:	(
</s>
<figure>
<s type="frag">
Figure	NNP	Figure
3	CD	3
</s>
</figure>
<s type="frag">
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="decl">
Such	JJ	such
results	NNS	result
point	VBP	point
out	RP	out
the	DT	the
significant	JJ	significant
moisturizing	JJ	moisturizing
effect	NN	effect
after	IN	after
using	VBG	use
the	DT	the
cosmetic	NN	cosmetic
under	IN	under
examination	NN	examination
and	CC	and
go	VBP	go
well	RB	well
with	IN	with
the	DT	the
rationale	NN	rationale
of	IN	of
the	DT	the
formulation	NN	formulation
,	,	,
based	VBN	base
on	IN	on
ingredients	NNS	ingredient
able	JJ	able
to	TO	to
moisturize	VB	moisturize
rapidly	RB	rapidly
the	DT	the
skin	NN	skin
and	CC	and
recover	VB	recover
the	DT	the
cutaneous	JJ	cutaneous
barrier	NN	barrier
to	TO	to
allow	VB	allow
it	PRP	it
to	TO	to
better	RBR	well
hold	VB	hold
the	DT	the
water	NN	water
present	JJ	present
into	IN	into
its	PRP$	its
outer	JJ	outer
layers	NNS	layer
.	.	.
</s>
</p>
<p>
<s type="decl">
<hi rend="italic">
In	IN	in
vivo	NN	vivo
</hi>
evaluation	NN	evaluation
of	IN	of
the	DT	the
efficacy	NN	efficacy
of	IN	of
a	DT	a
formulation	NN	formulation
for	IN	for
atopic	JJ	atopic
and	CC	and
very	RB	very
dry	JJ	dry
skin	NN	skin
(	-LRB-	(
Xerosis	NNP	Xerosis
)	-RRB-	)
was	VBD	be
done	VBN	do
.	.	.
</s>
</p>
<p>
<s type="decl">
An	DT	a
example	NN	example
of	IN	of
one	CD	one
topical	JJ	topical
formulation	NN	formulation
for	IN	for
atopic	JJ	atopic
dermatitis	NN	dermatitis
(	-LRB-	(
Table	NNP	Table
1	CD	1
)	-RRB-	)
based	VBN	base
on	IN	on
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
based	VBN	base
ingredient	NN	ingredient
is	VBZ	be
reported	VBN	report
below	RB	below
for	IN	for
illustrative	JJ	illustrative
and	CC	and
non-limiting	JJ	non-limiting
purposes	NNS	purpose
.	.	.
</s>
</p>
<p>
<s type="decl">
Purpose	NN	purpose
of	IN	of
the	DT	the
test	NN	test
:	:	:
To	TO	to
provide	VB	provide
active	JJ	active
substances	NNS	substance
through	IN	through
a	DT	a
form	NN	form
that	WDT	that
allows	VBZ	allow
a	DT	a
prompt	JJ	prompt
release	NN	release
and	CC	and
an	DT	a
effective	JJ	effective
amount	NN	amount
in	IN	in
atopic	JJ	atopic
dermatitis	NN	dermatitis
,	,	,
characterized	VBN	characterize
by	IN	by
a	DT	a
deteriorated	VBN	deteriorate
functionality	NN	functionality
of	IN	of
the	DT	the
barrier	NN	barrier
,	,	,
an	DT	a
increased	VBN	increase
transepidermal	NN	transepidermal
water	NN	water
loss	NN	loss
(	-LRB-	(
TEWL	NNP	TEWL
)	-RRB-	)
and	CC	and
a	DT	a
significant	JJ	significant
xerosis	NN	xerosis
,	,	,
as	RB	as
well	RB	well
as	IN	as
in	IN	in
the	DT	the
case	NN	case
of	IN	of
pathologies	NNS	pathology
associated	VBN	associate
with	IN	with
a	DT	a
local	JJ	local
subcutaneous	JJ	subcutaneous
microcirculation	NN	microcirculation
disorder	NN	disorder
.	.	.
</s>
<s type="decl">
The	DT	the
efficacy	NN	efficacy
of	IN	of
a	DT	a
topical	JJ	topical
cosmetic	JJ	cosmetic
formulation	NN	formulation
containing	VBG	contain
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
in	IN	in
comparison	NN	comparison
to	IN	to
a	DT	a
placebo	NN	placebo
has	VBZ	have
been	VBN	be
evaluated	VBN	evaluate
.	.	.
</s>
</p>
<p>
<s type="decl">
Mean	NN	mean
values	NNS	value
,	,	,
standard	JJ	standard
deviations	NNS	deviation
,	,	,
and	CC	and
variations	NNS	variation
were	VBD	be
calculated	VBN	calculate
for	IN	for
each	DT	each
set	NN	set
of	IN	of
values	NNS	value
.	.	.
</s>
</p>
<p>
<s type="decl">
Following	VBG	follow
the	DT	the
results	NNS	result
of	IN	of
normality	NN	normality
test	NN	test
(	-LRB-	(
Kolmogorov	NNP	Kolmogorov
–	:	-
Smirnov	NNP	Smirnov
test	NN	test
)	-RRB-	)
,	,	,
the	DT	the
instrumental	JJ	instrumental
data	NNS	datum
(	-LRB-	(
T0	CD	T0
,	,	,
T4	NN	T4
weeks	NNS	week
)	-RRB-	)
and	CC	and
the	DT	the
variations	NNS	variation
(	-LRB-	(
T4	NN	T4
weeks-T0	NNS	weeks-T0
)	-RRB-	)
were	VBD	be
statistically	RB	statistically
compared	VBN	compare
by	IN	by
means	NNS	means
of	IN	of
<hi rend="italic">
t	NN	t
</hi>
-test	NN	-test
for	IN	for
parametric	JJ	parametric
and	CC	and
dependent	JJ	dependent
data	NNS	datum
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
all	DT	all
cases	NNS	case
,	,	,
the	DT	the
groups	NNS	group
of	IN	of
data	NNS	datum
were	VBD	be
considered	VBN	consider
statistically	RB	statistically
different	JJ	different
for	IN	for
a	DT	a
probability	NN	probability
value	NN	value
<hi rend="italic">
p	NN	p
</hi>
&lt;	SYM	&lt;
0.05	CD	0.05
.	.	.
</s>
</p>
<p>
<s type="decl">
Protocol	NN	protocol
of	IN	of
double-blind	JJ	double-blind
study	NN	study
:	:	:
the	DT	the
product	NN	product
containing	VBG	contain
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
ingredient	NN	ingredient
and	CC	and
the	DT	the
placebo	NN	placebo
was	VBD	be
applied	VBN	apply
on	IN	on
the	DT	the
forearms	NNS	forearm
by	IN	by
20	CD	20
volunteers	NNS	volunteer
of	IN	of
either	CC	either
sex	NN	sex
(	-LRB-	(
1	CD	1
male	NN	male
and	CC	and
19	CD	19
females	NNS	female
with	IN	with
an	DT	a
average	JJ	average
age	NN	age
of	IN	of
50	CD	50
years	NNS	year
)	-RRB-	)
with	IN	with
atopic	JJ	atopic
and	CC	and
very	RB	very
dry	JJ	dry
skin	NN	skin
(	-LRB-	(
xerosis	NN	xerosis
)	-RRB-	)
,	,	,
twice	RB	twice
a	DT	a
day	NN	day
,	,	,
for	IN	for
4	CD	4
weeks	NNS	week
.	.	.
</s>
</p>
<p>
<s type="decl">
During	IN	during
the	DT	the
study	NN	study
,	,	,
subjects	NNS	subject
were	VBD	be
instructed	VBN	instruct
to	TO	to
wash	VB	wash
their	PRP$	their
body	NN	body
using	VBG	use
their	PRP$	their
current	JJ	current
skin	NN	skin
care	NN	care
regimen	NN	regimen
and	CC	and
to	TO	to
not	RB	not
apply	VB	apply
the	DT	the
tested	VBN	test
products	NNS	product
on	IN	on
any	DT	any
other	JJ	other
site	NN	site
than	IN	than
the	DT	the
prescribed	VBN	prescribe
ones	NNS	one
.	.	.
</s>
<s type="decl">
For	IN	for
the	DT	the
whole	JJ	whole
duration	NN	duration
of	IN	of
the	DT	the
test	NN	test
,	,	,
the	DT	the
subjects	NNS	subject
were	VBD	be
not	RB	not
allowed	VBN	allow
to	TO	to
use	VB	use
different	JJ	different
products	NNS	product
on	IN	on
the	DT	the
forearms	NNS	forearm
and	CC	and
instructed	VBN	instruct
to	TO	to
avoid	VB	avoid
UV	NN	UV
exposure	NN	exposure
.	.	.
</s>
</p>
<p>
<s type="decl">
Furthermore	RB	furthermore
,	,	,
the	DT	the
side	NN	side
of	IN	of
application	NN	application
(	-LRB-	(
left	JJ	left
or	CC	or
right	JJ	right
forearm	NN	forearm
)	-RRB-	)
of	IN	of
the	DT	the
two	CD	2
formulations	NNS	formulation
(	-LRB-	(
cream	NN	cream
containing	VBG	contain
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
based	VBN	base
ingredient	NN	ingredient
and	CC	and
placebo	NN	placebo
)	-RRB-	)
were	VBD	be
randomized	VBN	randomize
among	IN	among
the	DT	the
volunteers	NNS	volunteer
.	.	.
</s>
<s type="decl">
Each	DT	each
sample	NN	sample
was	VBD	be
labeled	VBN	label
“	``	''
right	JJ	right
”	''	''
or	CC	or
“	``	''
left	VBN	leave
”	''	''
,	,	,
indicating	VBG	indicate
the	DT	the
side	NN	side
of	IN	of
application	NN	application
of	IN	of
the	DT	the
product	NN	product
.	.	.
</s>
<s type="decl">
The	DT	the
assignment	NN	assignment
of	IN	of
subject	NN	subject
number	NN	number
and	CC	and
subsequent	JJ	subsequent
placement	NN	placement
on	IN	on
the	DT	the
randomization	NN	randomization
chart	NN	chart
were	VBD	be
made	VBN	make
in	IN	in
order	NN	order
of	IN	of
appearance	NN	appearance
at	IN	at
the	DT	the
study	NN	study
center	NN	center
on	IN	on
the	DT	the
first	JJ	first
day	NN	day
.	.	.
</s>
<s type="decl">
The	DT	the
products	NNS	product
were	VBD	be
given	VBN	give
to	IN	to
the	DT	the
subjects	NNS	subject
in	IN	in
anonymous	JJ	anonymous
containers	NNS	container
which	WDT	which
did	VBD	do
not	RB	not
provide	VB	provide
any	DT	any
information	NN	information
about	IN	about
the	DT	the
treatment	NN	treatment
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
comparisons	NNS	comparison
evidenced	VBD	evidence
statistically	RB	statistically
significant	JJ	significant
differences	NNS	difference
between	IN	between
studied	VBN	study
ingredient	NN	ingredient
and	CC	and
placebo	NN	placebo
for	IN	for
both	DT	both
parameters	NNS	parameter
(	-LRB-	(
hydration	NN	hydration
and	CC	and
TEWL	NNP	TEWL
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="decl">
This	DT	this
means	VBZ	mean
that	IN	that
the	DT	the
improvements	NNS	improvement
observed	VBD	observe
in	IN	in
the	DT	the
active	JJ	active
area	NN	area
were	VBD	be
statistically	RB	statistically
higher	JJR	high
than	IN	than
the	DT	the
improvements	NNS	improvement
observed	VBN	observe
in	IN	in
the	DT	the
placebo	NN	placebo
area	NN	area
.	.	.
</s>
</p>
<p>
<s type="decl">
Instrumental	JJ	Instrumental
measurements	NNS	measurement
of	IN	of
skin	NN	skin
hydration	NN	hydration
and	CC	and
transepidermal	JJ	transepidermal
water	NN	water
loss	NN	loss
(	-LRB-	(
TEWL	NNP	TEWL
)	-RRB-	)
were	VBD	be
performed	VBN	perform
on	IN	on
a	DT	a
selected	VBN	select
area	NN	area
(	-LRB-	(
9	CD	9
cm2	NN	cm2
)	-RRB-	)
of	IN	of
the	DT	the
forearms	NNS	forearm
at	IN	at
the	DT	the
baseline	NN	baseline
and	CC	and
after	IN	after
4	CD	4
weeks	NNS	week
of	IN	of
treatment	NN	treatment
.	.	.
</s>
</p>
<p>
<s type="frag">
<b>
Skin	NN	skin
Hydration	NN	hydration
</b>
</s>
</p>
<p>
<s type="decl">
A	DT	a
statistically	RB	statistically
significant	JJ	significant
increase	NN	increase
in	IN	in
the	DT	the
mean	JJ	mean
basal	JJ	basal
values	NNS	value
of	IN	of
skin	NN	skin
hydration	NN	hydration
was	VBD	be
evidenced	VBN	evidence
after	IN	after
4	CD	4
weeks	NNS	week
of	IN	of
application	NN	application
of	IN	of
both	CC	both
the	DT	the
ceramides	NNS	ceramide
and	CC	and
trehalose	NN	trehalose
based	VBN	base
ingredient	NN	ingredient
cream	NN	cream
and	CC	and
the	DT	the
placebo	NN	placebo
product	NN	product
(	-LRB-	(
Table	NNP	Table
2	CD	2
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="decl">
A	DT	a
statistically	RB	statistically
significant	JJ	significant
difference	NN	difference
between	IN	between
ceramides	NNS	ceramide
and	CC	and
trehalose	NN	trehalose
based	VBN	base
ingredient	NN	ingredient
cream	NN	cream
and	CC	and
placebo	NN	placebo
product	NN	product
was	VBD	be
detected	VBN	detect
after	IN	after
4	CD	4
weeks	NNS	week
of	IN	of
treatment	NN	treatment
(	:	(
</s>
<figure>
<s type="frag">
Figure	NNP	Figure
4	CD	4
</s>
</figure>
<s type="frag">
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
cream	NN	cream
containing	VBG	contain
trehalose	NN	trehalose
and	CC	and
ceramides	NNS	ceramide
based	VBN	base
ingredient	NN	ingredient
is	VBZ	be
able	JJ	able
to	TO	to
improve	VB	improve
skin	NN	skin
hydration	NN	hydration
if	IN	if
compared	VBN	compare
to	IN	to
placebo	NN	placebo
.	.	.
</s>
</p>
<p>
<s type="frag">
<b>
Transepidermal	NNP	Transepidermal
Water	NNP	Water
Loss	NNP	Loss
(	-LRB-	(
TEWL	NNP	TEWL
)	-RRB-	)
</b>
</s>
</p>
</text>